Background: Diverticular disease of the colon has a wide geographic variation and is a very common cause of hospital visits and admissions in the west. Contrary to this there is scarce data on colonoscopic prevalence of diverticular disease from our country. Aims and Objectives: To determine the prevalence of colonic diverticulosis and concomitant colonoscopic pathologies among patients undergoing colonoscopy in a tertiary care gastrointestinal endoscopy setting in Northern India. Materials and Methods: All adult patients who underwent colonoscopy for various indications and were diagnosed to have colonic diverticulosis from August 2016 to December 2019 in the Department of Gastroenterology, Shifa Medical centre, Srinagar, Kashmir, India were included in the study. Results: Out of a total of 4500 colonoscopic procedures, diverticulosis was seen in 190 cases with an overall prevalence of 4.2%. Fifty-six percent of these were males and 44% were females. In 77 (40.52%) patients diverticulosis was seen in left colon, in 72 (37.89 %) in right colon and in 41 (21.57 %) diverticulosis was noted in pancolonic distribution. Adenomatous polyps were seen in 27 % of the cases. Conclusion: Colonic diverticulosis has very low prevalence in this northern Indian state. Adenomatous polyps are commonly associated with this condition.
Abstracts Objectives: Direct acting antivirals (DAAs) have dramatically changed our approach towards management of chronic hepatitis C by yielding a high sustained virological response (SVR). Genotype-3 is the most common genotype found in Kashmir (Northern India) besides having an aggressive nature with increased risk of steatosis and hepatocellular carcinoma. We assessed the efficacy and safety of sofosbuvir plus valpatasvir based therapy in chronic hepatitis C genotype-3 infection in Kashmiri population. Aims and objectives: An observational, prospective, open label, hospital based study was carried over a period of two years which included 230 treatment naïve chronic hepatitis-C genotype-3 patients. Patients were divided in two groups. Group-A: Non-cirrhotics who received sofosbuvir (400 mg daily) with valpatasvir (100 mg) in fixed–dose combination for 12 weeks. Group B included CPT class A cirrhotics who received sofosbuvir (400mg daily) with valpatasvir (100 mg daily) and weight based ribavarin for 12 weeks. The primary end point was a sustained virologic response at 12 weeks after the end of therapy. Results and observations: We observed 98.57 % (138/140) SVR 12 in non-cirrhotics who received valpatasvir plus sofosbuvir treatment regimen. Cirrhotics who received Sofosbuvir plus valpatasvir with ribavirin observed SVR of 96.6 % (87/90). All patients tolerated the drug regimens well without any serious adverse effect. Conclusion: Once daily oral Sofosbuvir plus valpatasvir based fixed dose rerimen is highly efficient and safe in treatment of both cirrhotics and non-cirrhotic hepatitis C patients. Keywords: Direct acting antivirals; sustained virological response; Genotype; chronic hepatitis C
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.